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Cefuroxime levels were measured in cerebrospinal fluid (CSF) and serum of four
patients with traumatic brain injury following the implantation of intraventricular
catheters. The levels ranged from 0.15 to 2.03//g/mL in CSF and from 1.8 to
66.9 /ig/mL in serum. No ventriculostomy related infections were detected.
Introduction
Intracranial pressure (ICP) monitoring is fundamental in the treatment of patients with
severe traumatic brain injury (TBI). Intraventricular catheters (IVC) allow continuous
ICP monitoring as well as drainage of ventricular cerebrospinal fluid (CSF) in order
to reduce elevated ICP. However, the risk of ventriculostomy related infections (VRI)
exists (Rosner & Becker, 1976; Mayhall et ah, 1984; Clark et al., 1989). In order to
prevent VRI, an absolute aseptic surgical technique and sterile management is necessary
while the catheter is in place. Detailed information on penetration of antibiotics into
CSF of patients with TBI is lacking so the advantage of prophylaxis remains
controversial (Mayhall et al., 1984; Clark el al., 1989). However, cefuroxime is routinely
used in our clinic as a prophylactic antibiotic in patients with TBI during the time of
ventricular ICP monitoring and may be of benefit. Cefuroxime levels were monitored
in CSF and serum of patients with severe TBI who underwent ventriculostomy.
Relevant antibiotic concentrations were detected in CSF independently from the
integrity of the blood brain barrier.
Materials and methods
Patients
In 1994 a total of 31 patients with severe TBI received IVC at the Division of Trauma
Surgery, University of Zurich, Switzerland. All of them had a Glasgow Coma Score
(GCS) ^ 8 on arrival (Teasdale & Jennett, 1976) and showed varying abnormalities in
the computed tomography (CT). Table I shows the clinical details of four patients
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included in this study. After surgical treatment the patients were transferred to the
intensive care unit (ICU). The therapy followed a standardized protocol (Stocker et al.,
1995). VRI was diagnosed according to Mayhall (Mayhall et al., 1984) and pneumonia
was diagnosed according to the protocol (Stocker et al., 1995). The study was approved
by the University Hospital Medical Ethics Board, Zurich.
Intraventricular catheter insertion
IVC (Becker External Drainage, Pudenz-Schulte Medical Corporation, Goleta, CA,
USA) were used in brain injured patients for monitoring as well as for therapeutic
release of CSF when ICP exceeded 15 mmHg. The IVC were inserted under aseptic
conditions in the operating room.
Cefuroxime treatment
Cefuroxime (Zinacef*, Glaxo AG, Schoenbuehl, Switzerland) was given in all patients
prior to IVC implantation in doses of 1.5 g intravenously and continued at the same
dosage every 8 h for 10-25 days (Table I). Cefuroxime was administered as
recommended by the manufacturer.
Specimen collection and microbiology
The serum and CSF samples were drawn on day 2, 4 and 6 of the treatment period at
approximately 1.5 and 6 h (99 ± 13 min and 355 ± 8 min respectively, mean ± S.E.M.)
after the first dose of cefuroxime. The specimens were centrifuged at 170 g at 4°C for
10 min, divided into aliquots and frozen at — 70°C until analysis.
On a routine basis CSF samples were drawn every three to four days and screened
for bacterial infections. The IVC tips were tested after removal for bacterial colonisation
at the Institute for Medical Microbiology, University of Zurich.
Albumin analysis and blood brain barrier function
Albumin levels were measured in CSF and serum by automatized laser photometry
(BNA Automat, Behring Werke, Marburg, Germany). The CSF/serum albumin ratio
(QA) was utilized as a parameter for blood brain barrier (BBB) integrity (Reiber &
Felgenhauer, 1987).
High performance liquid chromatography (HPLC) analysis
Cefuroxime levels were determined by a reversed phase HPLC system (Waters-Millipore
Corp., Milford, MA, USA) using 40% methanol in 5 mM tetrabutylammoniumphos-
phate as mobile phase and photodiode array detection. The variability of the assay was
< 3 % , linearity was tested at 1.5-150 jig/mL, detection limits for serum and CSF
samples were 0.2 and 0.1 /ig/mL respectively.
Antibiotic prophylaxis in brain injured patients 163
Results and discussion
At our institution cefuroxime is used as a standard prophylactic antibiotic not only in
patients with severe TBI. In this study all patients received an IVC for measurement
and treatment of elevated ICP. Additionally the IVC offered the possibility of a
continuous monitoring of cefuroxime levels in the cerebral compartment. Table I
summarizes the clinical data. The IVC was in place for 20 to 26 days. Patient selection
was based on the single antibiotic prophylaxis with cefuroxime which was given from
the day of insertion and continued for at least 10 days (Table I). Our results clearly show
that cefuroxime enters the CSF of patients with TBI. Cefuroxime concentrations in CSF
ranged from 0.35 to 1.76 fig/mL at approximately 1.5 h after the first daily application
of cefuroxime (day 2, 4 and 6), whereas after about 6 h the levels ranged from 0.15 to
2.03 /ig/mL (Figure). The corresponding levels of cefuroxime in serum ranged between
2.0 and 61.7 /ig/mL after 1.5 h and between 1.8 and 66.9 /Jg/mL after 6 h. As indicated
in the figure, two samples (patient 2 at day 6 and patient 4 at day 2) were collected later
(after the second daily dose) and therefore these concentrations were higher. The
cefuroxime levels in the serum of our patients were highly variable. The use of IVC in
the treatment of brain injured patients is nowadays well established (Stocker et al.,
1995), despite the risk of infections (Mayhall et al., 1984; Clark et al., 1989). The device
must be implanted under aseptic conditions and the removal of CSF has to be
performed under sterile conditions.
The use of prophylactic antibiotics in patients with IVC is controversal (Mayhall
et al., 1984; Clark et al., 1989), chiefly due to the fact that the penetration of antibiotics
in the CSF of patients with severe TBI has not been studied, whereas numerous
pharmacokinetic studies have been performed in patients with meningitis (Ristuccia &
Le Frock, 1992).
Cefuroxime is a second generation cephalosporin with a broad antimicrobial
spectrum (Ristuccia & Le Frock, 1992) and is active against frequently encountered
bacteria, which can cause meningitis following neurosurgical procedures (Mayhall et al.,
1984). Cefuroxime reaches therapeutic concentrations in many body compartments
(Daikos et al., 1977), has a very low toxicity, and is excreted unmetabolized by the
urinary tract (Ristuccia & Le Frock, 1992). In meningitis cefuroxime has superior
penetration into the CSF compared to other cephalosporins (Daikos et al., 1977;
Ristuccia & Le Frock, 1992). In children with bacterial meningitis mean cefuroxime
concentrations in the CSF were 6.4 and 3.6 /ig/mL 2 h following iv doses of 50 mg/kg
of cefuroxime on days 2 and 14 of treatment. Without meningeal inflammation mean
cefuroxime concentration in CSF was 1.34 /ig/mL (Sirinavin et al., 1984). This finding
is comparable with our results. The minimal inhibitory concentration for sensitive
staphylococci and streptococci ranges from 0.1 to 1.4/ig/mL. Therefore, cefuroxime
concentrations in CSF of our patients are likely sufficient to inhibit most of the bacteria
found in VRI (Mayhall et al., 1984).
No patient in this study had a VRI, which was confirmed by microbiological analysis
of the CSF samples every 3 to 4 days during the period the IVC was in place.
Furthermore, the IVC-tips of all patients were analyzed after removal for bacterial
colonisation, but no bacterial infection was detected.
Systemic infections occurred during their treatment period in the ICU. The onset
of these infections was more than a week (7-14 days) following TBI. Three out of four
patients had pneumonia (Table II). The cefuroxime monotherapy was supplemented
Table I. Clinical details of the four patients studied
Patient
1
i
3
4
Sex/age
(years)
M/41
F/23
M/16
F/18
Other injuries
fractures of humerus, tibia.
calcaneus and patella
fracture of radius
facial fractures
fracture of radius
Duration
IVO (days)
20
24
26
20
Days in
ICU*
31
35
28
31
GOS'
5
5
4
5
VRI"
no
no
no
no
Antibiotic
prophylaxis
cefuroxime
cefuroxime
cefuroxime
cefuroxime
Duration
(days)
21
25
10
16
1
a
3
"Duration of intraventncular catheter in place.
Intensive care unit.
Glasgow Outcome Score at 6 months after trauma (Jennett el «/.. 1976)
''Ventnculostomy related infections.
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Figure. Cefuroxime concentrations (//g/mL) in CSF ((a)-(d)) and serum ((e)-(h)) of four brain injured
patients. Black columns show values after 1.5 h (99 ± 13 min) and white columns after 6 h (355 ± 8 min).
As indicated by asterisk (•) two samples (patient 2 at day 6 and patient 4 at day 2) were drawn after the
second daily administration of cefuroxime The CSF and serum levels reflect concentrations 45 min
(patient 2) and immediately (patient 4) after the second daily infusion of cefuroxime.
with different antibiotics according to microbiological evaluation of the broncho-
alveolar lavage and may have delayed the occurrence of VRI. However, previously the
onset of VRI has been reported predominantly within 5 days after insertion of the
IVC (Mayhall el al., 1984; Clark el al., 1989).
After a 6 month period the patients were examined again and none showed clinical
signs of late onset intracerebral infection. They had recovered to a varied extent and
had a GOS between 4 and 5 (Jennet el al., 1976).
In order to determine the influence of BBB function on the availability of cefuroxime
we analyzed the CSF/serum albumin ration (QA)- With the exception of patient 2, who
showed a moderate dysfunction of the BBB during the first 48 h, the QA of all patients
were below 0.007 indicating normal BBB function. Therefore, cefuroxime may reach the
CSF of these patients by diffusion or via active transport. Further studies are warranted
regarding the transport mechanisms of cefuroxime via the BBB.
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Table II. Systemic infections and treatment
Patient
1
2
3
4
Onset
on day
8
9
14
7
13
Systemic
infections
pneumonia
pneumonia
pneumonia
tracheo-bronchial
colonisation
vaginal-mycosis
Microbiology
Pseudomonas aeruginosa
Serratia marcescens
P. aeruginosa
Candida albicans
P. aeruginosa
C. albicans
Streptococcus consiellatus
Klebsiella spp.
Enterobacter cloacae
Stenotrophomonas maltophilia
Treatment
netilmicin
ciprofloxacin
amoxicillin +
clavulanic acid
netilmicin
ceftazidime
piperacillin
co-trimoxazole
ciprofloxacin
amoxicillin +
clavulanic acid
ceftazidime
vancomycin
econazol
In summary, our data show that cefuroxime reaches the CSF, suggesting that this
may be a suitable prophylactic antibiotic for the prevention of VRI in patients with TBI.
However, aseptic implantation of intraventricular catheters as well as sterile
management of the device are essential. A follow-up study will focus on elucidating the
exact pharmacokinetics of cefuroxime in the CSF of patients with TBI.
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